R&D assets
Materials · Methods · Intellectual Property
05 / INVESTOR RELATIONS
Long-term governance.
Lasting corporate value.
Connect R&D assets, commercial verification and corporate governance to establish a development path that can be understood and tested.
LEADERSHIP / SCIENCE & BUSINESS
Connecting scientific expertise with international business.
Chief Executive Officer · eGreen Biotek
Juiche Hsieh
Juiche Hsieh is CEO of eGreen Biotek and holds a master's degree in biochemistry from North Carolina State University, USA. His work connects Sanghuang cultivation and research with international business development and company management.
He previously served as International Marketing Manager at INComputer in the United States and Asia Business Division Manager at Advanced Medical Therapeutic, bringing cross-market communication and industry experience to eGreen's research and partnership strategy.
- Education
- North Carolina State University, USA · Master's in Biochemistry
Career at eGreen
- 2009–2016Chief Technology Officer
- 2016–presentChief Executive Officer
A FRAMEWORK FOR LONG-TERM VALUE
Long-term value needs inspectable evidence.
Understand a research company through technical assets, commercial validation and governance quality. These are information priorities, not financial forecasts or financing terms.
01Verifiable technical assets
＋
Material definitions, method versions, research records and IP scope. Distinguish documented work from remaining gaps.
02Sustainable commercial collaboration
＋
Scope, delivery standards, supply stability and market feedback. Separate historical partnerships from current execution status.
03Consistent governance information
＋
Finance, internal controls, decision rights, document versions and risk disclosure. Formal information follows company-approved disclosures.
LONG-TERM VALUE SYSTEM
Let technology and governance,
Form a continuous forward cycle.
Enterprise development structure does not represent financial forecasts or market rewards.
Commercial verification
Delivery · Quality · Supply
Governance and Information
Internal Control · Finance · Transparency
CAPITAL MARKETS / VERIFIED MILESTONE
GISA 7525: a milestone in company development.
Taipei Exchange announced on 15 September 2017 that eGreen Biotek would register on the Go Incubation Board for Startup and Acceleration Firms (GISA) on 20 September 2017. Clear company identification, historical records and disclosure connect research-led operations with capital-market communication.
GISA stock code7525
eGreen Biotek
eGreen Biotek Corp.
Taipei Exchange · GISA- Registration date
- Announced industry category
- Biotechnology & Medical Care
- Announcement date
- Board
- Taipei Exchange · GISA
Announcement reference: TPEx 10600256991
Official announcement checked: 2026.10.24
Registration announced
Company short name, stock code and scheduled registration date were specified.
GISA registration
7525 designated as the company's GISA stock code.
GISA is Taipei Exchange's advisory and equity-fundraising mechanism for innovative enterprises. It does not provide stock trading; GISA registration is distinct from listing on the TWSE, TPEx Main Board or Emerging Stock Board.
Our GISA registration is a historical milestone in our capital-market development. For current market status and formal disclosures, refer to the latest TPEx and eGreen announcements.
VALUE CREATION
Three interconnected
Long-term development foundation.
Capital market preparation is centered on traceable technology, actual operations and governance systems. The following is a development direction and does not constitute a financial forecast.
R&D assets
Accumulated strains and cultivation methods, component analysis, biological activity and manufacturing process research data. Evaluate research progress based on data completeness and reproducibility.
Focus / Materials, methods, intellectual property and evidenceCommercial verification
Promote business with clear cooperation scope, supply specifications and delivery conditions. Track technical exchanges, cooperation intentions and actual supply separately.
Focus on delivery, quality and continuity of cooperationGovernance and information quality
Gradually strengthen financial reporting, internal control and board of directors management information, and transform operating activities into viewable data.
Focus / Finance, internal control and transparent communicationREADINESS ROADMAP
Capital market layout,
Establish readiness first.
Building on our 2026 governance and operating plans, we are progressively strengthening capital-market readiness. Further steps are assessed against corporate resolutions, operating conditions and applicable rules.
Operational and Financial Fundamentals
Take operating efficiency, fund utilization and financial data quality as the basis for preparation. Distinguish achievable business advancements from unproven opportunities and avoid substituting expected results for operational performance.
Internal control and governance documentation
Improve monthly accounts, internal control and management tracking so that clear records of R&D investment, supply cooperation and operational activities can be left. Evaluate the professional assistance required based on company size and development stage.
Strategic Funding and Path Assessment
After the governance and operational foundations are met, evaluate strategic cooperation, professional guidance and appropriate capital market paths. Public offering, listing or other application procedures are subject to separate evaluation and formal disclosure.
Following the governance plans presented at the ROC year 115 annual shareholders' meeting, we are advancing financial and internal-control readiness. Financial figures and fundraising terms are disclosed only after formal approval.[C2]
Information Disclosure Principles
Historical milestones, current results and future plans are marked respectively. R&D results are attached to the research stage, cooperation matters are disclosed based on actual documents and the scope of disclosure; financial and capital market matters are subject to official announcements and approval documents.
This page is a company introduction and is not a securities offering, solicitation or investment advice.
THE NEXT QUESTION STARTS HERE
Based on R&D foundation,
Look towards long-term development.
eGreen indoor Sanghuang cultivation record
EGREEN / CULTIVATION & RESEARCH
From Sanghuang to the cultivation floor.
From the golden fruiting bodies of eGreen LED-cultivated Sanghuang to cultivation and R&D, explore the connections between materials, technology and research.
SCIENCE CONNECTS US
The next question is worth exploring together.
Discuss materials, methods and the next stage of validation with research teams, pharmaceutical companies and strategic partners.
Start a conversation